Q-omics provides the consensus-scored ZNF107 profile across patient tissues and cancer cell-line models. ZNF107 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF107 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, ZNF107 RNA expression shows 20,922 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where ZNF107 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF107 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF107 survival associations across molecular data types. ZNF107 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF107 RNA expression–survival associations across cancer types. High ZNF107 expression shows unfavorable associations in UVM, ACC, KICH, KIRC and COAD, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF107 RNA expression.
This table summarizes ZNF107 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF107. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF107 shows higher tumor expression in BLCA, HNSC, KIRP, LUAD, STAD and LUSC. The BLCA box plot shows higher ZNF107 RNA expression in tumor versus normal tissue (log2 FC = +1.466, t-test p < 0.001).
This table shows molecular features associated with ZNF107 in patient tissues and cancer cell lines. In patient samples, ZNF107 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF107 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
